The Journal of Heart and Lung Transplantation
Volume 23, Issue 12 , Pages 1451-1454 , December 2004

Successful treatment of Fusarium proliferatum pneumonia with posaconazole in a lung transplant recipient

  • Raoul Herbrecht, MD

      Affiliations

    • Department of Hematology and Oncology, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France
    • Corresponding Author InformationReprint requests: Raoul Herbrecht, MD, Département d’Hématologie et d’Oncologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France. Telephone: +33-388-12-76-88. Fax: +33-388-12-76-81.
    • ,
  • Romain Kessler, MD

      Affiliations

    • Department of Pulmonology, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France
    • ,
  • Christine Kravanja, PharmD

      Affiliations

    • Department of Hematology and Oncology, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France
    • ,
  • Marie-Hélène Meyer, PharmD

      Affiliations

    • Department of Hematology and Oncology, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, 67098 Strasbourg, France
    • ,
  • Jocelyn Waller, MD

      Affiliations

    • Institute of Parasitology and Tropical Pathology, Strasbourg, France
    • ,
  • Valérie Letscher-Bru, PharmD

      Affiliations

    • Institute of Parasitology and Tropical Pathology, Strasbourg, France

Received 30 June 2003 ,Revised 1 September 2003 ,Accepted 29 September 2003.

References 

  1. Sampathkumar P, Paya CV. Fusarium infection after solid-organ transplantation. Clin Infect Dis. 2001;32:1237–1240
  2. Barrios NJ, Kirkpatrick DV, Murciano A, Stine K, Van Dyke RB, Humbert JR. Successful treatment of disseminated Fusarium infection in an immunocompromised child. Am J Pediatr Hematol Oncol. 1990;12:319–324
  3. Richardson SE, Bannatyne RM, Summerbell RC, Milliken J, Gold R, Weitzman SS. Disseminated fusarial infection in the immunocompromised host. Rev Infect Dis. 1988;10:1171–1181
  4. Letscher-Bru V, Campos F, Waller J, Randriamahazaka R, Candolfi E, Herbrecht R. Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J Clin Microbiol. 2002;40:1100–1102
  5. Arney KL, Tiernan R, Judson MA. Primary pulmonary involvement of Fusarium solani in a lung transplant recipient. Chest. 1997;112:1128–1130
  6. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–917
  7. Ponton J, Ruchel R, Clemons KV, et al.  Emerging pathogens. Med Mycol. 2000;38(suppl 1):225–236
  8. Summerbell RC, Richardson SE, Kane J. Fusarium proliferatum as an agent of disseminated infection in an immunosuppressed patient. J Clin Microbiol. 1988;26:82–87
  9. Dromer F, Improvisi L, Dupont B, Loebenberg D. In vitro and in vivo activity of SCH-56592 (posaconazole) against Aspergillus fumigatus. J Mycol Med. 2002;12:52–57
  10. Laverdiere M, Hoban D, Restieri C, Habel F. In vitro activity of three new triazoles and one echinocandin against Candida bloodstream isolates from cancer patients. J Antimicrob Chemother. 2002;50:119–123
  11. Dannaoui E, Meletiadis J, Mouton JW, Meis JF, Verweij PE. In vitro susceptibilities of Zygomycetes to conventional and new antifungals. J Antimicrob Chemother. 2003;51:45–52
  12. Meletiadis J, Meis JF, Mouton JW, Rodriquez-Tudela JL, Donnelly JP, Verweij PE. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother. 2002;46:62–68
  13. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH. In vitro activities of investigational triazoles against Fusarium species (effects of inoculum size and incubation time on broth microdilution susceptibility test results). Antimicrob Agents Chemother. 2002;46:3298–3300
  14. Ezzet F, Wexler D, Courtney R, Laughlin M, Batra V. The pharmacokinetic properties of posaconazole in fasted healthy subjects: basis for clinical dosage recommendations. Proceedings of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. 2002; September 27–30, San Diego, California
  15. Ascioglu S, Rex JH, de Pauw B, et al.  Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants (an international consensus). Clin Infect Dis. 2002;34:7–14
  16. Pujol I, Guarro J, Gene J, Sala J. In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains. J Antimicrob Chemother. 1997;39:163–167
  17. Rabodonirina M, Piens MA, Monier MF, Gueho E, Fiere D, Mojon M. Fusarium infections in immunocompromised patients (case reports and literature review). Eur J Clin Microbiol Infect Dis. 1994;13:152–161
  18. Herbrecht R, Neuville S, Letscher-Bru V, Natarajan-Ame S, Lortholary O. Fungal infections in patients with neutropenia (challenges in prophylaxis and treatment). Drugs Aging. 2000;17:339–351
  19. Johnson LB, Kauffman CA. Voriconazole (a new triazole antifungal agent). Clin Infect Dis. 2003;36:630–637
  20. Hachem RY, Raad II, Afif CM, et al.  An open, non-comparative multicenter study to evaluate efficacy and safety of posaconazole (SCH 56592) in the treatment of invasive fungal infections (IFI) refractory (R) to or intolerant (I) to standard therapy (ST). Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2000; September 17–20, Toronto, Ontario, Canada (abstract 1109)
  21. Lozano-Chiu M, Arikan S, Paetznick VL, Anaissie EJ, Loebenberg D, Rex JH. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother. 1999;43:589–591

PII: S1053-2498(03)00519-9

doi: 10.1016/j.healun.2003.09.033

The Journal of Heart and Lung Transplantation
Volume 23, Issue 12 , Pages 1451-1454 , December 2004

Article Tools

* Image Usage & Resolution